Hormonal
In insulin-resistant women with prior GDM, plasma adiponectin levels decrease further over a 1-year follow-up period, even in the absence of changes in body weight, body fat composition, or glucose tolerance.
If you have a history of GDM and are insulin-resistant, your protective adiponectin levels may drop over time even if you maintain your weight. This suggests that metabolic health can decline independently of body composition. Regular monitoring of insulin sensitivity is crucial to catch this decline early.
Of note, adiponectin further decreased (P < 0.05) only in insulin-resistant pGDM despite unchanged body fat content and distribution after a 1-year follow-up.
Why this rating
The longitudinal follow-up data is robust, showing a statistically significant decrease (P < 0.01) in the specific subgroup (n=16) despite stable anthropometric measures.
Source
Plasma Adiponectin, Insulin Sensitivity, and Subclinical Inflammation in Women With Prior Gestational Diabetes Mellitus
Christine Winzer et al. · Diabetes Care · 2004
DOI 10.2337/diacare.27.7.1721
More from this paper
- Women with prior gestational diabetes mellitus (pGDM) exhibit significantly lower plasma adiponectin concentrations compared to women with normal glucose tolerance (NGT), independent of body fat mass and insulin sensitivity.Good
- Lower plasma adiponectin in women with prior GDM is associated with subclinical inflammation, indicated by higher levels of C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →